Please use this identifier to cite or link to this item: https://doi.org/10.1002/lt.20685
Title: Prophylactic strategies for Hepatitis B patients undergoing liver transplant: A cost-effectiveness analysis
Authors: Dan, Y.Y.
Wai, C.T. 
Yeoh, K.G. 
Lim, S.G. 
Issue Date: May-2006
Source: Dan, Y.Y., Wai, C.T., Yeoh, K.G., Lim, S.G. (2006-05). Prophylactic strategies for Hepatitis B patients undergoing liver transplant: A cost-effectiveness analysis. Liver Transplantation 12 (5) : 736-746. ScholarBank@NUS Repository. https://doi.org/10.1002/lt.20685
Abstract: Hepatitis B immunoglobulin with lamivudine prophylaxis (LAM/HBIG) is effective in preventing Hepatitis B (HBV) recurrence posttransplant but is expensive and inconvenient. Lamivudine-resistant HBV, which has limited the usefulness of lamivudine monoprophylaxis in transplant, can now be effectively controlled with adefovir dipivoxil. We performed a cost-effectiveness analysis on the strategies of lamivudine prophylaxis with adefovir rescue(LAM/ADV) compared to combination LAM/intravenous fixed high-dose HBIG prophylaxis(LAM/ivHBIG) or LAM/intramuscular HBIG prophylaxis(LAM/imHBIG). Markov modeling was performed with analysis from societal perspective. Probability rates were derived from systematic review of the literature and cost taken from MEDICARE database. Outcome measures were incremental cost-effectiveness ratio(ICER) and cost to prevent each HBV recurrence and death. Analysis was performed at 5 years posttransplant as well as at end of life expectancy (15 years). Combination LAM/ivHBIG cost an additional USD562,000 at 15 years, while LAM/imHBIG cost an additional USD139,000 per patient compared to LAM/ADV. Although there is an estimated increase in recurrence of 53% with LAM/ADV and 7.6% increased mortality at the end of life expectancy (15 years), the ICER of LAM/ivHBIG over LAM/ADV treatment is USD760,000 per quality-adjusted life-years and for LAM/ imHBIG, USD188,000. Cost-effectiveness is most sensitive to cost of HBIG. Lamivudine prophylaxis with adefovir dipivoxil salvage offers the more cost-effective option for HBV patients undergoing liver transplant but with higher recurrence and death rate using a model that favors LAM/ HBIG. Lowering the cost of HBIG maintenance will improve cost-effectiveness of LAM/HBIG strategy. In conclusion, a tailored approach based on individual risks will optimize the cost-benefit of HBV transplant prophylaxis. © 2006 AASLD.
Source Title: Liver Transplantation
URI: http://scholarbank.nus.edu.sg/handle/10635/131538
ISSN: 15276465
DOI: 10.1002/lt.20685
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

53
checked on Jan 17, 2018

WEB OF SCIENCETM
Citations

44
checked on Nov 17, 2017

Page view(s)

8
checked on Jan 14, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.